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Abstract A major challenge in biomedical optics is the
accurate quantification of in vivo fluorescence images.
Fluorescence imaging is often used to determine the pharma-
cokinetics of photosensitizers used for photodynamic therapy.
Often, however, this type of imaging does not take into
account differences in and changes to tissue volume and
optical properties of the tissue under interrogation. To address
this problem, a ratiometric quantification method was
developed and applied to monitor photosensitizer meso-tetra
(hydroxyphenyl) chlorin (mTHPC) pharmacokinetics in the
rat skin-fold observation chamber. The method employs a
combination of dual-wavelength excitation and dual-
wavelength detection. Excitation and detection wavelengths
were selected in the NIR region. One excitation wavelength
was chosen to be at the Q band of mTHPC, whereas the
second excitation wavelength was close to its absorption
minimum. Two fluorescence emission bands were used; one
at the secondary fluorescence maximum of mTHPC centered
on 720 nm, and one in a region of tissue autofluorescence. The
first excitation wavelength was used to excite the mTHPC and
autofluorescence and the second to excite only autofluores-
cence, so that this could be subtracted. Subsequently, the
autofluorescence-correctedmTHPC image was divided by the
autofluorescence signal to correct for variations in tissue
optical properties. This correction algorithm in principle
results in a linear relation between the corrected fluorescence
and photosensitizer concentration. The limitations of the
presented method and comparison with previously published
and validated techniques are discussed.
Keywords Meso-tetra(hydroxyphenyl) chlorin (mTHPC
Foscan®) . Ratio fluorescence imaging technique . mTHPC
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Introduction
The primary response to photodynamic therapy (PDT) is
determined by the tissue oxygenation, light fluence (rate),
and local concentration of the photosensitizer. The biolog-
ical activity of the photosensitizer within the illuminated
volume is related to the concentration of the fluorescent
active form of the photosensitizer. Thus, optical imaging of
photosensitizer fluorescence (using light doses much lower
than are necessary for PDT damage) aids the understanding
of PDT by monitoring the photosensitizer spatial distribu-
tion and its fluorescence activity.
For many years, observation chambers implanted in
various animal species and in humans have been used for
intravital microscopy of living tissue [1–12]. Through the
possibility to transplant neoplastic tissue within the cham-
ber, the skin-fold observation chamber was especially
developed to monitor the early vascular events, anti-tumor
effects, and pharmacokinetics of photosensitizers.
However, the ability to accurately quantify the in vivo
measured fluorescence is critical [13, 14]. The fluorescence
S. Kaščáková :B. Kruijt :H. S. de Bruijn :
A. van der Ploeg-van den Heuvel :H. J. C. M. Sterenborg :
A. Amelink :D. J. Robinson (*)
Center for Optical Diagnostics and Therapy, Department
of Radiation Oncology, Erasmus Medical Center,
Room Ee-1675, PO Box 2040, 3000 CA, Rotterdam,
The Netherlands
e-mail: d.robinson@erasmusmc.nl
S. de Visscher :M. J. H. Witjes :A. Amelink
Department of Oral and Maxillofacial Surgery,
Division of Oncology, University Medical Centre Groningen,
Groningen, The Netherlands
ORIGINAL ARTICLE
In vivo quantification of photosensitizer fluorescence
in the skin-fold observation chamber using dual-wavelength
excitation and NIR imaging
Slávka Kaščáková & Sebastiaan de Visscher & Bastiaan Kruijt & Henriëtte S. de Bruijn &
Angélique van der Ploeg-van den Heuvel & Henricus J. C. M. Sterenborg &
Max J. H. Witjes & Arjen Amelink & Dominic J. Robinson
Received: 24 September 2010 /Accepted: 5 January 2011 /Published online: 29 January 2011
Lasers Med Sci (2011) 26:789–801
DOI 10.1007/s10103-011-0888-z
signal originates not only from the photosensitizer but also
from various other fluorescent molecules naturally present in
the tissue that can cause an unknown and variable amount of
background autofluorescence [15]. Moreover, the measured
fluorescence signal is also influenced by geometric factors
(the distance and the angle of the excitation and detection
source relative to tissue surface) and the tissue optics
(scattering and absorption of the excitation and fluorescence
emission light in the tissue). For example, tissues with higher
background absorption coefficients, e.g., due to high melanin
or blood content, can decrease the propagation of both the
excitation and fluorescence emission light. This is further
complicated by the fact that the absorption spectrum of
blood depends on its oxygenation. In addition, tumor tissue
is less scattering than normal tissue [16–18] and the
thickness for the different types of tissue within the chamber
varies as well. In general, the tumor within the chamber is
thicker than the normal tissue. Furthermore, normal tissue
can also show variability in thickness at the different sites
within the chamber. Since the collected fluorescence image
is influenced by all of the factors discussed above (optical
properties of the tissue, tissue autofluorescence, chamber
thickness variations, and geometric illumination and collec-
tion factors), an imaging methodology that corrects for these
factors is necessary to obtain quantitative photosensitizer
fluorescence images.
Several techniques have been developed to correct the
measured fluorescence for tissue autofluorescence, absorp-
tion, and scattering properties of the tissue and variations in
irradiance, excitation geometry, and detection efficiency.
Profio [19] calculated the ratio of fluorescence marker
signal over the reference autofluorescence. Baumgartner et
al. [20] and Witjes et al. [21] described a subtraction
method where the autofluorescence background signal is
subtracted using dual-wavelength excitation. In our group,
Sinaasappel and Sterenborg developed the double ratio
technique based on dual-wavelength excitation and dual-
wavelength detection [15] and more recently Saarnak et al.
[22] published a ratiometric method based on measuring the
autofluorescence signal prior to marker administration.
Bogaards et al. [14] reviewed the performance of these
correction methods for various input parameters over
ranges that can be expected during in vivo imaging around
a standard set of optical properties representing those for
human skin. The study revealed that the subtraction method of
Baumgartner et al. [20] corrected the detected fluorescence
signal of the marker for variations in autofluorescence, but
was unable to correct for variations in irradiance, excitation
geometry, and tissue optical properties. The ratiometric
methods of Profio [19], Sinaasappel and Sterenborg [15],
and Saarnak et al. [22] completely corrected for variations in
irradiance, excitation geometry, and detection efficiency. The
correction for tissue optical properties was to a great extent
also achieved using ratiometric methods. However, the
method of Profio [19] remained dependent on changes in
autofluorescence. The method of Saarnak et al. [22]
demonstrated the best quantification performance, as it
depends only on the concentration of the fluorophore. This
method is based on image acquisition before and after
fluorophore administration, and it requires that these
subsequent images be taken from the same tissue site
under an identical geometry. Here the assumption was
made that the optical properties and autofluorescence may
change spatially within the image, but remain constant
over the time interval between image acquisitions. How-
ever, these conditions are typically not met during window
chamber pharmacokinetics experiments. Especially the
assumption that autofluorescence, tissue optical properties,
and tissue thickness remain constant over the time period
for which marker pharmacokinetics is studied (typically
over periods of up to 7 days) may not be valid. In this
case, the method of Sinaasappel and Sterenborg [15],
which does not have such restrictive conditions with
respect to window chamber changes over time, was
revealed to be a better option for fluorophore quantifica-
tion. However, the double ratio method of Sinaasappel and
Sterenborg [15] suffers from a significant drawback: the
relation between marker fluorescence and marker concen-
tration is non-linear and saturates for high marker
concentrations. This severely limits the applicability of
the double ratio correction technique for determining
absolute fluorophore concentrations for the study of
photosensitizer pharmacokinetics where large variations
(several orders of magnitude) in fluorophore concentra-
tions need to be quantified [14, 22].
In summary, two important factors limit the quantifica-
tion performance of state-of-the-art ratiometric methods :
(1) the remaining dependence of the methods on time-
dependent variations in autofluorescence, tissue optical
properties, and tissue thickness [14], and (2) the relation
between marker fluorescence and marker concentration is
non-linear and saturates for high marker concentrations. In
the present study, we address both issues using a novel
ratiometric method that corrects for time-dependent varia-
tions in tissue thickness and tissue optical properties and
features a linear response even for high photosensitizer
concentrations. In addition, in our method, we minimize the
dependence of the fluorescence signal on tissue optical
properties by selecting the excitation and emission
wavelengths in the red and in the near infrared (NIR),
where the tissue absorption and scattering coefficients are
relatively small and do not vary much with wavelength
[14]. We have applied our method to measure the
pharmacokinetics of the second–generation photosensitizer
5,10,15,20-tetra (m-hydroxyphenyl) chlorin (m-THPC) in the
rat skin-fold observation chamber.
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Experimental procedures
Materials mTHPC (Foscan®) (c=4 mg mTHPC/ml dis-
solved in PEG, EtOH, water-free solution) was obtained
from Biolitec pharma (Edinburgh, The United Kingdom).
Alexa Fluor 720 was obtained from Invitrogen (Breda,
The Netherlands). Polyethylene glycol 400 (PEG400),
Evans Blue, and Titanium dioxide (TiO2) were obtained
from Sigma-Aldrich (Zwijndrecht, The Netherlands) and
96% ethanol (EtOH)was purchased fromMerck (Amsterdam,
The Netherlands).
Preparation of mTHPC and administration Stock solution
of mTHPC was dissolved in a solution of PEG400:EtOH:
water=3:2:5 (v/v) to a concentration c=0.126 mg/ml. The
solution was stored in the dark for at least 30 min prior to
injection, after which the sample was determined to be
stable, i.e., no changes in fluorescence peak intensity were
detected. To investigate the state of photosensitizer after 30
min from mixing with PEG:EtOH:H2O mixture, the
absorption spectra of mTHPC were recorded in the
concentration range c=0.11 – 200 μM. Over the concen-
tration range, the spectrum of mTHPC did not change and
the solution accurately followed Beer’s law with no
evidence of spectral peak broadening or shifts in absorption
maxima. The same species of mTHPC, i.e., the monomer, is
present at the concentration administrated to the animal.
The prepared mTHPC solution was administered intrave-
nously at a dose of 0.15 mg kg−1 body weight under
isoflurane/O2/N2O anesthesia.
Animal model The animal experiment committee of the
Erasmus Medical Center approved the experimental design
for this study. Skin-fold observation chambers were
prepared using a slightly modified technique to the one
that has been described previously [10, 23]. Briefly, the
chamber was prepared on the back of female Fischer-344
rats (weight m=144±3 g) in four operations (carried out
under general isoflurane/O2/N2O anesthesia) during the
period of 2 weeks. As a result of these operations, a thin
layer of subcutaneous tissue was clamped between mice
and a cover slide. In the first operation, sterile air (12 ml)
was subcutaneously injected on the back of the rat to gently
separate the skin from the underlying tissue. In the second
operation, a plastic ring and a cover slide was positioned
under the skin above the subcutaneous tissue matching the
vessels. The third operation was proceeding on the second
week. During this operation, the skin was folded, prepared
and fixed in the splint. Finally, during the last operation, the
mammary adenocarcinoma (R3230AC) tumor was trans-
planted in the layer of normal tissue, reached by unscrewing
the cover slide on top of the chamber. Within 5–7 days, the
chamber was ready for treatment, i.e., the tumor was
supported by blood vessels and had visibly grown. Ideally
the chamber contained fat cells and capillaries over an area of
approximately 1 cm in diameter with some supporting
arterioles and venules.
Experimental set-up for fluorescence and transmission
imaging A schematic diagram of the experimental setup is
presented in Fig. 1. The mTHPC fluorescence pharmaco-
kinetics in the chamber model was investigated in time after
intravenous mTHPC administration. The experimental time
points were: 0 min (before mTHPC administration) and
5 min, 2 h, 4 h, 8 h, 24 h, 48 h, and 96 h after mTHPC i.v.
injection. The localization of photosensitizer within the
chamber was visualized by acquiring fluorescence and
transmission images with two excitation laser light sources:
a dye laser of 629 nm pumped by an argon ion laser
(Spectra Physics, Darmstadt, Germany) and a 652-nm
diode laser (Biolitec pharma, Edinburgh, The United
Kingdom). Light was coupled from a bifurcated optical
fiber using a system of condensing lenses into the base of a
heated X-Y stage to produce a uniform distribution of both
excitation wavelength lights through the sample. The
fluence rate of each excitation illumination was 0.6 mW/
cm2 and the excitation fields were uniform and equal. For
fluorescence and transmission imaging, light transmitted
through the chamber was collected using an f2,8/105 mm
macro lens and imaged onto a CCD camera (ORCA-ER,
Hamamatsu, Japan). The macro lens can be used to zoom in
on a specific area within the sample resulting in a square
field of view of 4.5 mm. Detection filters were placed in a
filter wheel (L.O.T.-Oriel, Stratford, USA) between the
macro lens and the CCD camera in order to obtain the
fluorescence (band-pass filter 720±10 nm (Omega Optical,
Blattleboro, USA), long-pass filter 763 nm (transmission:
763–1,050 nm, Omega Optical, Blattleboro, USA)) and
transmission (neutral density filter with 10% transmission
for excitation wavelength light sources 652 nm and
629 nm, Omega Optical, Blattleboro, USA). To eliminate
Fig. 1 The schematic diagram of the experimental setup
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the presence of excitation light in the fluorescence
detection channels, the identical long-pass filters of
690 nm (transmission: 690–1,050 nm, Omega Optical,
Blattleboro, USA), were placed together with band-pass
filter 720±10 nm and long-pass filter 763 nm. In
addition, to shield the CCD camera from very long
wavelength light, a short-pass filter of 850 nm (trans-
mission: 845–585 nm, blocking: 880–1,100 nm, L.O.T.-
Oriel, Stratford, USA) was placed between the exit of the
filter wheel and the CCD camera. The integration time of
the camera was 30 s for each excitation and a filter
combination was used to visualize tissue fluorescence.
The fluence delivered during these measurements was
approximately 0.072 J cm−2 per measurement time point.
The total fluence delivered to each chamber was approx-
imately 0.504 J cm−2 during the course of the experiment.
Between measured time points, animals were conscious
and placed in a dark and warm environment.
Principle of correction method The ratiometric method
used in this study is illustrated in Fig. 2, where the in vivo
absorption and emission spectra of mTHPC are presented
with the combined transmission characteristics of the filters
used for fluorescence detection.
The method presented here is based on dual-wavelength
excitation and dual-wavelength detection: One excitation
wavelength is chosen to be at an absorption maximum of
mTHPC and the other at its absorption minimum. The two
emission wavelengths are chosen to be at the secondary
fluorescence maximum of mTHPC (at λ=720 nm) and in
the region of no photosensitizer fluorescence. The reason
for such a wavelength selection was to detect the changes in
the amount of mTHPC fluorescence and monitor the
autofluorescence changes in real time. The excitation of
mTHPC with 652-nm wavelength (Q-band absorption
maximum of mTHPC (Fig. 2)) will produce the highest
fluorescence compared to excitation by any other wave-
length in the red region of the mTHPC spectra. The second
excitation wavelength was 629 nm. This excitation wave-
length corresponds to an absorption minimum of mTHPC
(Fig. 2). Therefore, excitation of mTHPC with 629-nm
wavelength leads to only small amounts of mTHPC
fluorescence emission at 720 nm. Furthermore, the fluores-
cence of mTHPC decreases rapidly beyond 730 nm (with a
minimal fluorescence for wavelengths above 750). There-
fore, excitation at 629 nm and detection of fluorescence for
wavelengths longer than 763 nm will give us information
on how background autofluorescence changes with time. It
is important to note that fluorescence emission detected in
the band-pass filter 720±10 nm (1exc=652 nm) is a spectral
convolution of mTHPC fluorescence and background
autofluorescence. Therefore, correction for background
autofluorescence in the band-pass filter 720±10 nm is
necessary. For this purpose, the subtraction of fluorescence
signal detected in the band pass filter 720±10 nm by
excitation at 629 nm was included. Subsequently, to ensure
correction for tissue optical properties, this difference is
divided by the autofluorescence signal excited by 629-nm
wavelength and detected in the region of wavelengths
longer than 763 nm.
Two assumptions are made: (1) the excitation at 629-nm
and 652-nm wavelengths lead to the same autofluorescence,
i.e., difference in yield of fluorescence for the tissue
fluorescence by excitation at 652 nm and 629 nm is
minimal; (2) the excitation by 629-nm wavelength does not
lead to mTHPC fluorescence detection at wavelengths
longer than 763 nm.
Subtraction and division of the images was performed
according to the following formula:
R ¼ F lexc652nm; lemisBP720nmð Þ  F lexc629nm; lemisBP720nmð Þ
F lexc629nm; lemisLP763nmð Þ ;
ð1Þ
where F(1exc 652 nm, 1emis BP 720 nm) is the fluorescence
image detected by excitation light source of 652 nm in the
wavelength region 720±10 nm; F(1exc 629 nm, 1emis BP 720 nm)
is fluorescence image registered by excitation light of
629-nm wavelength and fluorescence detected in the wave-
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Fig. 2 Schematic excitation (black line) and emission spectra
(excitation wavelength 652 nm) (green line) of mTHPC based on in
vivo measurement from rat muscle tissue 16 h from i.v. injection of
mTHPC (c=0.15 mg.kg−1). The red line shows the tissue autofluor-
escence (excitation wavelength 652 nm) measured in vivo from rat
muscle tissue. Presented spectra are based on previous measurements
monitoring mTHPC in muscle tissue using differential path length
spectroscopy (DPS) and fluorescence differential path length spec-
troscopy (FDPS) [32]. The figure also includes transmission character-
istics of band-pass filter 720±10 nm (dash dot green line) and long-
pass filter 763 nm (dash-dot red line) in combination with short-wave
pass filter 850 nm (used to shield the CCD camera from very long
wavelength light)
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length region 720±10 nm and F(1exc 629 nm, 1emis LP 763 nm) is
the image excited by wavelength 629 nm, fluorescence
detection for the wavelength region>763 nm.
Image analysis Image analysis was performed using the
Labview 7.1 (National Instruments Corporation, Austin,
USA). Images were first corrected for background and
minor variations in fluence rate of the corresponding
excitation light sources. In the second step, the sequence
of fluorescence images from each animal was registered
by translation and rotation using anatomical landmarks
identified in the corresponding transmission images. In
the next step, binning of the pixels was performed (4x4)
to increase the signal-to-noise ratio. After the pixel
binning, the images were resized on the same size of
16-bit image at a resolution of 1344 × 1024 pixels. The
registration of images from the second step of analysis
enabled us to determine the fluorescence intensity of
each tissue type from the same area as follows: in the
corresponding transmission image the regions of interest
were chosen for each tissue type. Tumor and normal
tissue regions of interest were chosen so that no large
vessels were in, or close to, the region. Thus in every
animal, three regions of interest were chosen for normal
tissue, three regions of interest selected inside the tumor,
and, depending on the vessel’s content, three up to five
regions of interest were selected within the vessels. The
same selected regions of interest were also applied for
images corrected by ratio imaging technique, where the
subtraction and division of the images was done accord-
ing to Eq. (1).
To investigate the validity of our ratiometric imaging
correction technique, we analyzed vessels of various
diameters. Blood vessel diameter was estimated from the
transmission images. According to determined square field
of view of macro lens, one picture element (pixel)
corresponds to approximately 3 μm.
Statistics In the present study, three female Fischer-344 rats
were used to determine autofluorescence and
transmission-intensity profiles. However, the mTHPC
pharmacokinetics profile was evaluated just in one
animal. The aim of our current study is to present the
correction method and not to validate the mTHPC
pharmacokinetics profile. Presentation of the results from
one animal avoids the increase in standard deviations due
to intra-animal (biological) variations.
Student’s t test was used to determine significance for
the difference in autofluorescence signal measured by two
different excitation light sources. Results with a p value
below 0.05 were considered significant. Statistical analysis
was done using Microcal Origin, version 6.0 (Microcal
Software, Inc., Northampton, MA).
Results
Window chamber tissue optical properties
and autofluorescence
Figure 3 shows the white light images of the chamber
model immediately before mTHPC injection and 96 h later.
Tumor tissue is easily recognized as a circular area of
higher light transmission compared to the surrounding
normal tissue. Vessels can be recognized as visually darker
tissue, i.e., more light-absorbing areas. In comparison with
the first day of the experiment (Fig. 3a), after 96 h (Fig. 3b),
the natural changes in the chamber model are clearly
visible. The tumor size increased and the position of the
vessels surrounding the tumor changed.
Figure 4 demonstrates the transmission intensity time
profile of 652-nm excitation light collected from different
tissue types within the transmission images of the chamber.
In comparison with the vessels and normal tissue, the
transmission intensity of the light is highest for the tumor
tissue. The lowest light transmission is detected from the
vessel’s area. The difference is visible for all observation
time points. Within the time, no significant changes in the
A) 
B) 
Fig. 3 White light reflection images of a chamber acquired (a) before
and (b) 96 h after mTHPC adminisration
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transmission profile of 652-nm excitation light are detected
in any of the tissue types, i.e., the intensity of the
transmission light does not change in time.
In Fig. 5, the difference between fluorescence intensities
of the background autofluorescence (measured before
mTHPC administration) excited by wavelengths 629 nm
and 652 nm, detected in the emission channels (band-pass
720±10 nm and long-pass 763 nm) is presented. For both
detection channels, for the same tissue type, the fluorescence
intensity using 652-nm excitation was not significantly
different (p>0.05) from the 629-nm excitation.
Figure 6 shows the autofluorescence kinetics (excitation
at 629 nm, long-pass filter 763 nm). The fluorescence
kinetics for all tissues changed in the same manner, i.e.,
from the measurement time points beyond 24 h, an increase
in fluorescence intensity is detected. The autofluorescence
signal from the vasculature is 1.2 times lower than for
normal tissue and 1.5 times lower in comparison with
fluorescence intensity detected in the tumor area.
Fluorescence pharmacokinetics of mTHPC
In Fig. 7, the time profile of the chamber model after
mTHPC administration is demonstrated. Figure 7a shows
the time profile of chamber transmission images. The
time-dependent evolution of the uncorrected fluorescence
images (excitation 652 nm, detection BP 720) of mTHPC
pharmacokinetics within the chamber model is shown in
Fig. 7b. In all uncorrected fluorescence images, the
borders of the chamber are clearly visible due to the
fluorescence properties of the plastic ring surrounding the
chamber.
Figure 7c shows the mTHPC uncorrected fluorescence
pharmacokinetic profile within the different tissue types.
Five minutes after mTHPC administration, the fluorescence
intensity is highest in the vessels and decreases for longer
time points. Four hours after mTHPC administration the
difference of fluorescence observed in vessels and other
tissue types reduces and from time points beyond 8 h after
mTHPC administration the fluorescence distribution in
tumor and normal tissue is similar. Normal and tumor
tissue showed no significant difference in fluorescence
intensity over the investigated period and follow the same
type of kinetic profile (Fig. 7c): between 5 min and 8 h, the
fluorescence intensity does not change significantly, while
above the 8-h time point, an increase in fluorescence is
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Fig. 4 Transmission-intensity time profile of 652-nm excitation light
collected from different tissue types : (▲) vessels, ( ) normal tissue,
and (○) tumor area. The standard deviation for time point within the
tissue type was calculated from region of interests of three control
animals (in every animal, three up to five regions of interest were
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observed. The intensity increased up to 48 h after mTHPC
administration and decreased for the 96-h time point. For
all incubation time points, the standard deviations are
higher for normal tissue than for tumor tissue or vessel area.
The time-dependent evolution of the corrected fluores-
cence images of mTHPC (images corrected by ratio
imaging technique, formula [1]) within the chamber is
shown in Fig. 7d. According to transmission images
(Fig. 7a), at time point 5 min from mTHPC administration,
only vessels show fluorescence. The intensity of fluores-
cence within the vessels decreased for longer incubation
time points. At t=4 h the contours of the vessels are not as
clear anymore due to mTHPC penetration through vessel
walls into the tissue. For t>8 h after mTHPC administration
the fluorescence is now within all structures of the chamber.
Note that the fluorescence of the plastic ring (Fig. 7b) is not
visible in any of corrected images (Fig. 7e).
The time dependence of the corrected fluorescence
intensity for the different tissue types is plotted in Fig. 7e.
The signal detected from the vessels shows high variations
(large error bars) for times below 24 h. The variation was
highest for 5 min followed by decreasing variations for
longer incubation time points. Beyond 24 h, these varia-
tions minimized. In contrast, variations of the corrected
fluorescence signal for normal tissue and tumor tissue are
small throughout the time-course of the experiment.
Vessel diameters
Figure 8 shows the corrected fluorescence signal as a
function of time from mTHPC administration detected in
vessels of different diameters. The pharmacokinetic profile
of mTHPC fluorescence is similar for all vessels: 5 min
after mTHPC administration, the fluorescence intensity
appears to be the highest, followed by a decrease for longer
time points. Between 24 and 96 h, no significant changes of
fluorescence intensity are detected. However, the corrected
fluorescence signal in Fig. 8 demonstrates large differences
in fluorescence intensity for the different vessel diameters.
With decreasing vessel diameter, the fluorescence intensity
decreases. The difference of fluorescence intensity is
highest for early time points after mTHPC i.v. administra-
tion (t<24 h): the highest difference is detected for the 5-
min time point followed by a decrease in difference up to
8 h. Between the 24 and 96-h time points, the fluorescence
intensity does not show any dependence on vessel diameter.
Discussion
We have investigated the use of a ratiometric imaging
technique for monitoring the kinetics of mTHPC fluorescence
in the rat skin-fold observation chamber. The chamber model
was specifically designed for monitoring the pharmacokinet-
ics of photosensitizers used in PDT. However, a problem
associated with fluorescence measurements is the difficulty of
obtaining quantitative fluorophore fluorescence, due to
varying optical properties of tissues and differences in tissue
thickness. This has important consequences for the general
interpretation of fluorescence measurements in the window
chamber. For example, in a previous study, our group
determined the spatial distribution of the kinetics of protopor-
phyrin IX (PpIX) fluorescence during ALA-PDT [11]. PpIX
fluorescence kinetics were measured in different tissue types
and conclusions were based on data that was not corrected for
differences in tissue optical properties and differences in the
thickness within and between window chambers. Although
the conclusions were based on determining the rate of
fluorescence increase in each tissue type separately, temporal
variations in tissue optical properties and differences in the
thickness of different tissues were not considered. This may
be of particular importance, especially when the relationship
between the increase of PpIX fluorescence with distance from
an arteriole and venule was investigated. Thus in the present
study, our intention was to investigate the difference in optical
properties of different types of tissue and its time changes in
the chamber model. Themethodology proposed here accounts
for the wavelength dependence of tissue optical properties and
overcomes the non-linearity of previously published ratio-
metric methods.
Tissue optical properties of chamber
Figures 4, 5, 6 clearly show the differences between the
fluorescence and transmission intensity acquired from
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Fig. 7 The time profile of the
chamber model (the same
window chamber as one
analyzed for Fig. 6) after
mTHPC administration. a Time
profile of chamber transmission
images after mTHPC
administration. b Time profile of
uncorrected fluorescence
emission images (652-nm
excitation, 720±10-nm
detection) of a chamber after
mTHPC administration. c The
time-dependent evolution of the
corrected fluorescence images of
chamber model after mTHPC
administration. d mTHPC
pharmacokinetics profile
(uncorrected fluorescence
signal: 652-nm
excitation, 720±10-nm
detection) for different tissue
types: (▲) vessels, ( ) normal
tissue and (○) tumor area. e
mTHPC
pharmacokinetics profile
(corrected fluorescence signal)
within the different tissue types:
(▲) vessels, ( ) normal tissue
and (○) tumor area
796 Lasers Med Sci (2011) 26:789–801
different types of tissue during the course of the experi-
ment. The fluorescence intensity detected from vessels was
lower than that from normal or tumor tissue. Considering
the blood content within these vessels and the absorption
spectra of oxy- and deoxy hemoglobin, the result observed
in Fig. 5a or b is not surprising. The same effect is also
evident in the transmission-intensity profile from different
tissue types (Fig. 4), and in the transmission images of the
chamber (Fig. 7a). The chamber vasculature represents the
tissue with the highest absorption coefficient, which
significantly attenuates the propagation of light. In contrast,
tumor tissue exhibits higher autofluorescence intensity than
the normal tissue area (Figs. 5, 6). This might be caused by
(1) a lower absorption coefficient of tumor tissue; (2) a
different scattering coefficient of tumour tissue (it is not
evident whether a higher or lower scattering coefficient
would result in a higher fluorescence yield); (3) a larger
thickness of tumour tissue; (4) a higher native fluorophore
concentration in the tumor tissue. Most likely, a combina-
tion of these factors results in the observed difference.
Since the raw fluorescence signal is confounded by each of
these factors, the differences in (and changes to) optical
properties of the tissue under interrogation will lead to
significant quantification errors of photosensitizer fluores-
cence within the chamber. Clearly a method that corrects
for the influence of these effects would be a step forward.
Validation of assumptions
In the study of Bogaards et al. [24], it was shown that the
performance of imaging techniques can be improved by
selecting the excitation and emission wavelengths towards
the NIR. Thus, in this study, the excitation wavelengths
were carefully selected between 620 and 840 nm, where the
tissue absorption and scattering are relatively small. In
addition, the combination of exciting tissue fluorescence at
a wavelength where the photosensitizer absorbs minimally
and detection at the wavelength of no photosensitizer
fluorescence, allowed us to monitor kinetics of tissue
autofluorescence during the course of the experiment.
According to the principle of the method we have presented
(Eq. 1), the assumption was made that both excitation
wavelengths used in this study lead to the same autofluor-
escence. This assumption is confirmed in Fig. 5, where the
fluorescence intensity detected from different tissue types
of control animals is plotted. Within the same tissue type,
the fluorescence intensity was not significantly different
using 629- and 652-nm excitation.
The second assumption underlying our correction algo-
rithm is that only signals from tissue autofluorescence can
be detected in the wavelength region>763 nm, using 629-
nm wavelength excitation. This choice of wavelengths was
0
2
4
6
8
10
12
Co
rre
ct
ed
 fl
uo
re
sc
en
ce
 in
te
ns
ity
 [ -
 ] 
Measurement in time [ hours ]
0 2 4 6 8 24 48 72 96
Fig. 8 Corrected fluorescence signal as a function of the time from
mTHPC administration, detected in the vessels of different diameter:
(■) 104 μm, (△) 83 μm and (▽) 47 μm
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Fig. 7 (continued)
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based on the minimal absorption of mTHPC at the
excitation wavelength and on the lack of mTHPC emission
in the wavelength region>763 nm (Fig. 2). In Fig. 6, we did
not detect any changes of autofluorescence within the first
measured time points in any of the tissue types. In contrast,
mTHPC fluorescence pharmacokinetics profile (excitation
652 nm, fluorescence detection at 720±10 nm; Fig. 7c),
revealed large differences in fluorescence intensity within the
vessels 5 min after the mTHPC administration. It is very
unlikely that there are changes of tissue autofluorescence
over the timescale of these first few measurements compared
to the first measurement of autofluorescence (at t=0).
Therefore, we conclude that the increase of fluorescence
intensity observed in chamber vessels in the band-pass filter
720±10 nm (Fig. 7b, c) is due to fluorescence emission of
mTHPC. The fact that this effect was not seen in Fig. 6
confirmed that the signal detected in the wavelength region>
763 nm (using 629-nm wavelength excitation) is solely due
to tissue autofluorescence.
Temporal changes of tissue optical properties
within the chamber
The detection of autofluorescence within the timeframe of
the experiment (Fig. 6) revealed that the autofluorescence
kinetics for all tissues changed in the same manner, i.e., for
measurement time points above 24 h there is a (steady)
increase in autofluorescence intensity. The cause of the
observed effect might be chamber thickness changes and/or
the changes in tissue optical properties at later time points.
Unfortunately, our data does not present conclusive
evidence as to which of these effects is dominant. The fact
that these changes occur within the time-course of the
experiment demonstrates the necessity for a correction
method, since the marker fluorescence will be affected by
these chamber changes similar to the autofluorescence.
Fluorescence pharmacokinetics of mTHPC
Figures 4, 5, and 6 clearly illustrate the necessity of an
appropriate correction technique for quantitative measure-
ment of photosensitizer fluorescence in the window chamber.
If we were to base conclusions on the pharmacokinetics
profile of mTHPC from Fig. 7c (uncorrected fluorescence
profile), then the tumor/normal tissue ratio is significantly
higher at early time points after mTHPC administration.
Taking into account Figs. 4, 5, and 6, this is actually due to a
larger thickness and/or smaller absorption/scattering content
of tumor tissue, rather than due to a higher mTHPC
concentration within the tumor. The larger standard deviation
associated with data detected from normal tissue can be
explained by thickness inhomogeneities and due to the
presence or absence of micro-capillaries. These variations
are only visible at high magnification and are difficult to
avoid in a model where normal tissue has a significant
component of microvasculature.
The correction of raw fluorescence data using the
ratiometric correction method that we presented results in
a significant decrease in the spatial variation associated
with a single measurement time point (evidenced by
smaller error bars) and does not report a significant
difference between the profile of mTHPC pharmacokinetics
between tumor and normal tissue up to 24 h after the
administration of mTHPC (Fig. 7e). In addition, we observe
that in all uncorrected images, a fluorescent border to the
chamber is clearly visible (Fig. 7b). This is due to the
presence of a fluorescent plastic ring on which the chamber
is mounted. Corrected fluorescence images do not show
this artifact (Fig. 7d).
Limitations of the correction method
As expected, the uncorrected signals (Fig. 7c) showed
larger intra-chamber variations (visible as error bars) than
the signal corrected using the ratiometric technique
(Fig. 7e). The exception to this trend was observed in
vessels where the error bars were still high at early time
points. These large error bars for mTHPC in vessels at early
time points are caused by averaging contributions from
small and large vessels, combined with vessel-diameter-
dependent mTHPC fluorescence yields for early time
points. The dependence of corrected mTHPC fluorescence
pharmacokinetics profile as a function of vessel diameter
(Fig. 8) shows that for larger diameter vessels we obtained
a higher fluorescence intensity of mTHPC than for small
vessels. We believe that the origin of this effect is due to a
limitation of our correction method, which is illustrated by
considering the spatial distribution of absorbers and
fluorophores within the vasculature at early time points
(Fig. 9). While it is well known that there are a number of
circulating endogenous fluorophores within the vessels,
such as water-soluble porphyrins and erythrocytes them-
selves [25–27], the autofluorescence from the window
chamber vasculature is likely to be dominated by the
contribution from connective tissue of vessel walls (in
particular the tunica media) and the surrounding tissue. For
early time points, mTHPC is primarily localized in the
blood plasma [28–31]. Thus localization of mTHPC is
inhomogeneous with respect to the tissue background
autofluorescence (Fig. 9b). Since our ratiometric method
corrects for tissue optical properties and chamber thickness
using the background autofluorescence, our method is most
suitable for situations where the marker fluorescence and
autofluorescence are co-localized; a condition that is not
met in case of mTHPC at early time points. A confirmation
of our hypothesis is the absence of a dependence of
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mTHPC fluorescence on vessel diameter for later time
points (between 24 and 96 h). Here the progressive re-
distribution of mTHPC from the plasma into and through
the vasculature into normal tissue results in a correction that
is not influenced by the different spatial distribution of
autofluorescence and marker fluorophore. This re-
distribution of mTHPC is in accordance with the previously
published pharmacokinetic profile of mTHPC in blood and
other tissues [28–31]. Plasma mTHPC levels are high
immediately after mTHPC injection (5 min after i.v.
administration) and decrease exponentially thereafter. In
mice and rats, mTHPC shows a bi-exponential decline with
half-life values of 0.5-1.3 h for the initial decline and 6.9-
20.9 h for the elimination phase [28–31].
Optical phantoms and double ratio imaging
We tested the performance of our correction algorithm in
optical phantoms. To maintain the geometry of our
transmission measurements and to avoid the precipitation
of scattering centers, we prepared solid silicone phantoms
containing mTHPC. We chose to use the absorber Evans
Blue and TiO2 to simulate tissue absorption and scattering.
Preparing solid phantoms with spectral properties that
match those of mTHPC and tissue autofluorescence in vivo
proved to be very challenging. Unfavorable spectral shifts
and changes in extinction coefficients and fluorescence
quantum yield were observed in dyes we selected to match
the optical properties of tissue. For example, the choice of
phantom autofluorophore was particular difficult. We found
that in silicone Alexa-Fluor 720 had a negligible fluores-
cence quantum yield whereas Evans Blue showed signifi-
cant fluorescence at both excitiation wavelengths. Given
these problems, we chose to compare our correction
algorithm with a previously validated ratiometric technique,
in which a double ratio (DR) is formed using two excitation
and two detection wavelengths [15]. The result of this
analysis can be seen in Fig. 10, where the mTHPC
pharmacokinetic profile within the different tissue types is
presented. A comparison of the present correction method
(Fig. 7e) shows a similar pharmacokinetics profile for all
tissue types. However, there is an important difference
between DR profiles in areas of very high fluorescence
intensity, in particular for short administration times in
vessels. The non-linear relationship between double ratio
and fluorophore concentration is a well-understood effect of
double ratio imaging [14]. This saturation effect is a
significant limitation of the DR correction technique for
determining absolute fluorophore concentrations that are
necessary for the study of pharmacokinetics, as discussed
previously.
It is clear that the method we present as well as the DR
correction technique have important limitations [14] and it
is important to stress that the choice of the fluorescence
detection technique and correction method should be based
on a specific application. This is particularly true for the
most appropriate selection of excitation wavelengths and
detection wavelength bands. It is important to note that we
have applied our correction method in a study investigating
mTHPC detection. The application of this technique to
different photosensitizers (or other fluorescent species)
should involve the careful consideration of the spectro-
scopic properties of the photosensitizer, so that autofluor-
escence can be measured during the course of the study in
real time and the method remains linearly dependent on
photosensitizer concentration.
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Fig. 10 mTHPC pharmacokinetics profile (corrected fluorescence
signal by double ratio fluorescence imaging technique of Sinaasappel
and Sterenborg [15]) within the different tissue types: (▲) vessels,
( ) normal tissue and (○) tumor area
B)A)
Fig. 9 Schematic representation of a limitation of the correction
technique a The same distribution pattern of fluorescence signal for
fluorophore (filled gray area) and background tissue (hashed area). b
Vertical profile of tissue with vessels of different diameter. Vessel is
shown as an ellipse within the tissue. Localization of fluorophore
(gray) is inhomogeneous compared to the tissue background fluores-
cence (open hashed area)
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Conclusions
In summary, we have shown that the raw fluorescence
intensity collected from tissues in the skin-fold observation
chamber varied significantly between different tissue types
and during the period of the investigation. Therefore, any
method that does not correct for tissue optical properties
and changes in autofluorescence leads to fluorescence
quantification errors. We have shown that a ratiometric
imaging method utilizing NIR autofluorescence detection
can be applied and corrects for differences and changes in
tissue optical properties and thickness. A limitation of our
method is that for very early time points after the
photosensitizer administration, a dependence on vessel size
was found due to a mismatch in localization of marker
fluorophore and background autofluorescence. Other than
this limitation, the method we present shows a high
sensitivity even for high photosensitizer concentrations.
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